LAG3
Lymphocyte activation gene 3 protein
As of the edition of 20 October 2026, LAG3 (lymphocyte activation gene 3 protein, UniProt P18627) has 15 drugs tested at it and 16 companies on the list, 8 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P18627
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 6
- Disease areas
- Cancer; Skin and connective tissue; Digestive system; Urinary and reproductive; Pregnancy and women's health; Lungs and airways; Blood and lymph; Immune system
- Registered trials of its drugs
- 204
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 6 |
| Stopped | 7 |
| Status not established | 1 |
| Total | 15 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Relatlimab | Marketed | Phase 4 | Ends 2034 |
| Fianlimab | Active | Phase 3 | none listed |
| Eftilagimod alfa | Active | Phase 3 | none listed |
| Favezelimab | Active | Phase 3 | none listed |
| Tobemstomig | Active | Phase 2 | none listed |
| Tebotelimab | Stopped | Phase 3 | none listed |
| Tuparstobart | Stopped | Phase 2 | none listed |
| BI 754111 | Stopped | Phase 2 | none listed |
| Ieramilimab | Stopped | Phase 2 | none listed |
| HLX26 | Stopped | Phase 2 | none listed |
| AK129 | Active | Phase 2 | none listed |
| GSK2831781 | Stopped | Phase 2 | none listed |
12 of 15 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 8 |
| Route B | 1 |
| Engaged | 6 |
| Undetermined | 1 |
| Total on the list | 16 |
| Company | Route |
|---|---|
| Bristol Myers Squibb | Route B |
| Incyte | Route A |
| Novartis | Route A |
The other 13 companies at LAG3
In the product16 companies in all; 13 are not named here, and no score is.
See the 16 companies at LAG3, ranked, with the facts behind eachRequest access. Nothing is shown until you do.